DBV Technologies Announces FDA Has Informed Co. That During Ongoing Biologics License Application For Viaskin Peanut, It Has 'identified questions regarding efficacy, including the impact of patch-site adhesion'; PAC Meeting To No Longer Take Place Mar 15
Benzinga Newsdesk